4D Molecular Therapeutics, Inc. (FDMT) research
4D Molecular Therapeutics, Inc.- Sector
- Biotechnology
- Last price
- $15.24
- As of
4D Molecular Therapeutics, Inc. (FDMT): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-13.
As of . Source: SEC EDGAR filings for FDMT. Method and limitations.
Share the FDMT intelligence card
See FDMT live in the terminal
Track FDMT's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live FDMT terminal, freeActive signals for FDMT
- highCONSENSUS_BUY
3 tracked funds increased FDMT this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +1183% to FDMT (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +4280% to FDMT (2026Q2)
- highINSTITUTIONAL_SURGE
D. E. Shaw & Co., Inc. added +85% to FDMT (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +1183% to FDMT (2026Q2)
FREE, NO ACCOUNT
Every signal on FDMT, as it fires
You are seeing 5 of 13 signals recorded on FDMT since 2026-06-10.
The five above landed across 2 days. The other 8 were recorded on 2 other days. 10 of the 13 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in FDMT (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 35104E100 · 2026Q2 | $9.1M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 35104E100 · 2026Q2 | $8.2M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 35104E100 · 2026Q2 | $924K | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 35104E100 · 2026Q2 | $590K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, FDMT
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
FDMT against its peers
FDMT's operating margin of -187.2% ranks in the 35th percentile of 12 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | FDMT | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 85.2M USD | 76.2M USD | 54 | 13 |
| Operating margin | -187.2% | -44.2% | 35 | 12 |
| Net margin | -164.4% | -19.0% | 35 | 12 |
| Return on equity | -27.7% | -37.1% | 72 | 22 |
Peers (23): WVE, OLMA, ACHV, RIGL, GERN, ARDX, GYRE, TBPH, CLYM, IMMX, ANNX, DBVT, SGP, AVTX, PHAR, SANA, DSGN, SLN, CADL, SLDB, ZVRA, CTMX, LXRX. Left out: ETRA (no annual filing), IVA (period gap). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (FDMT: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more FDMT signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to FDMTand get the insider, 13F, options, and confluence read in one view.